

The amniotic membrane as a biological scaffold, its preparation and use in regenerative medicine in Slovenia

Tina Cirman,¹ Taja Železnik Ramuta,² Zala Lužnik,³ Marko Hawlina,³ Petra Schollmayer,³ Dragica Smrke,⁴ Mateja Erdani Kreft²

Abstract

Amniotic membrane (AM) is the innermost layer of the placenta, surrounding and protecting the embryo. AM is a multilayered tissue composed of amniotic epithelial cells, amniotic mesenchymal stromal cells, basal lamina, and stroma. AM's properties, which are the result of its structural features, render it extremely useful for therapeutic purposes, since it enhances epithelialisation, is a substrate for cell growth, decreases fibrosis and tissue neovascularisation and has antimicrobial properties. Due to its mechanical properties, which are mostly a result of the basal lamina's and stroma's extracellular matrix, and different growth factors that it contains, AM is increasingly used as a biological scaffold in regenerative medicine.

Regenerative medicine is an interdisciplinary field of research and clinical applications, utilising principles of biological and engineering sciences for the development of viable tissue or organ substitutes. In regenerative medicine, we distinguish between three approaches: 1) engraftment of functional cells (including stem cells) into the damaged or defective tissue; 2) reshaping of the damaged or defective tissue using synthetic or natural materials; and 3) tissue engineering, i.e. the use of scaffolds for the enhancement of the growth of tissue-specific cells and development of new, regenerated tissue. Furthermore, we present the use of AM as a biological scaffold in regenerative medicine in Slovenia.

Cite as: Cirman T, Ramuta TŽ, Lužnik Z, Hawlina M, Schollmayer P, Smrke D, Kreft ME. [The amniotic membrane as a biological scaffold, its preparation and use in regenerative medicine in Slovenia]. *Zdrav Vestn.* 2018;87(11–12):530–46.

DOI: 10.6016/ZdravVestn.2684

¹ Blood Transfusion Center of Slovenia, Ljubljana, Slovenia

² Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

³ Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia

⁴ Division of surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia

Korespondenca/

Correspondence:

Mateja Erdani Kreft,
e: mateja.erdani@mf.uni-lj.si

Ključne besede:

amnijska membrana;
biološki nosilec;
regenerativna medicina;
oftalmologija;
dermatologija; urologija;
matične celice

Key words:

amniotic membrane;
biological scaffold;
regenerative medicine;
ophthalmology;
dermatology; urology;
stem cells

Received: 2. 1. 2018

Accepted: 15. 10. 2018

1 The structure and properties of the amniotic membrane

The placenta is composed of the maternal and foetal parts. The latter consists of chorion (outer layer) and amniotic membrane (innermost layer) (1). Amniotic membrane (AM) is a non-innervated and non-vascularised 0.02–0.5 mm thick structure that surrounds and protects an embryo or foetus during pregnancy, and maintains homeostasis of the amniotic fluid (2) (Figure 1A). It is formed by a monolayer of amniotic epithelial cells (AEC), basal lamina and a three-layered connective tissue (stroma). Stroma is composed of a compact layer, a layer of amniotic mesenchymal stromal cells (AMSC) and a spongy

layer. The spongy layer of AM borders to the chorion. The basal lamina forms the boundary between the epithelium and stroma (Figure 1B) (3).

Cell junctional proteins between AEC (occludin, claudin-3 and claudin-4, desmoplakin) together with the elements of the extracellular matrix of the basal lamina and AM stroma (collagen type I, III, IV, V, VI, laminin, fibronectin, hyaluronan and other proteoglycans) contribute significantly to the integrity and biochemical properties of AM.

Proteins, located in different layers of the stroma (collagen type I, III, IV, V, VI, VII, laminin and fibronectin) function as a *cell substrate* (6,9-13). Laminin and fibronectin enable cell attachments, function as a substrate and accelerate epithelial cell migration. Therefore, it is not surprising that AM promotes epithelization (14-18).

AM contains different growth factors, among them epidermal growth factor (EGF), transforming growth factor alpha (TGF- α), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF) and transforming growth factor β_1 and β_2 (TGF- β_1 and - β_2) (19-22). Growth factors in AM are found *ex vivo* in concentrations ranging from a few pg per mg to a few pg per g of fresh tissue (23,24). They perform different functions: they promote epithelization and cell differentiation, inhibit inflammation, fibrosis, apoptosis and tissue vascularisation and exhibit antimicrobial activity (25).

AEC also express anti-inflammatory proteins such as receptor antagonist interleukin-1 (IL-1RA) and IL-10 (26,27). Different cell types (e.g. corneal and limbal stem cells, corneal keratocytes, and conjunctival epithelial cells), treated with an AM extract or cultured on AM, expressed lower amounts of pro-inflammatory interleukins-1 α and -1 β ,

interleukin-2, interferon- γ (IFN- γ), tumour necrosis factor- α (TNF- α) and interleukin-6 (28-32). Due to its anti-inflammatory action, AM reduces fibrosis and tissue neovascularisation (2,31).

AM also displays antimicrobial activity *in vivo*. The presence of histones H2A and H2B, which are known for their antimicrobial and endotoxin-neutralising activity, was determined in the cytoplasm and on AEC plasma membrane (33). The presence of cDNA for cystatin E was demonstrated in AEC, which suggests that these cells probably produce cystatin E, a cysteine protease inhibitor and can further contribute to the AM antioxidant effect (36). In AEC, antimicrobial elafin and defensin- β molecules were also detected (34,35).

Like on other embryonic tissues and cells, human leukocyte antigens -A, -B, -C and -DR (HLA) are very weakly expressed on the AEC. Therefore AM transplantation does not cause acute immune response (37). There was no rejection of human AM in xenotransplantation (38). The expression of HLA-G, which plays an important role in triggering immune tolerance, was also demonstrated on the AEC.

2 Amniotic membrane as a scaffold in tissue engineering

The task of tissue engineering is to develop tissue substitutes that restore, maintain or improve tissue function (40). Tissue regeneration or replacement of poorly functioning or dysfunctional organs can be achieved by a combination of suitable scaffolds (synthetic or biological), cells and bioactive molecules (41-44).

An important step in tissue engineering is the choice of an appropriate scaffold material. Scaffolds should provide a suitable environment for cell growth and




Figure 1: Structure of the placenta: A) Amniotic membrane (AM) is the inner layer of the placenta, providing the protection and support to the foetus *in vivo*. B) AM consists of the epithelial monolayer, thick basal lamina and connective tissue (stroma).

differentiation and enable the formation of a functional tissue substitute after *in vivo* transplantation while being effectively integrated into the host tissue (45). Furthermore, they must be biocompatible (i.e. not causing toxic, carcinogenic or immune response and be resistant to inflammation) (3), degradable (gradually being replaced with the body's own cells) and should have mechanical properties, appropriate for the site of the implantation (45,46). Natural (biological) materials are a common choice in tissue engineering as they contain natural bioactive molecules that promote growth and differentiation (47). Since it is relatively easy to harvest (the use of AM is acceptable from ethical point of view, considering the placenta is usually discarded after the birth), as well as to process and transport, of all biological materials AM has been in use the longest. AM

is biologically compatible, it has adequate mechanical properties (permeability, stability, elasticity, flexibility, plasticity) and the potential for growth factor delivery (3).

The major disadvantages for the wider use of AM in clinical practice are 1.) non-standardised procedures for AM preparation and storage, 2.) biological variability of AM, and 3.) low mechanical strength of AM (49). Other materials, such as collagen, fibrin, siloxane-hydrogel, polycaprolactone, gelatine-chitosan, etc., are often used as scaffolds for eye surface reconstruction (48).

Possible modes of using AM as a scaffold are shown in Table 1 and Figure 2. For instance, AM as a scaffold for the epithelial cells, obtained either from limbus biopsies or from the biopsies of the oral mucosa, is most often used for the reconstruction of the ocular surface (48).

Table 1: Overview of AM use as a scaffold for the culturing of different cell types and tissues and as a scaffold for drugs.

AM as a scaffold for:	Reference	Notes
Corneal/limbal epithelium with limbal epithelial stem cells	Koizumi et al., 2000 (19,23), Grueterich et al., 2003 (119), Shortt et al., 2007 (120), Tsai et al., 2000 (121), Sharma et al., 2011 (122), Mariappan et al., 2010 (123), Ang et al., 2010 (124), Pathak et al., 2016 (125), Zakaria et al., 2014 (126), Vazirani et al., (127)	For transplantation of cultured corneal/epithelial epithelium <i>ex vivo</i> , which contains limbal epithelial stem cells (LESC) in clinical studies or as a routine therapeutic method only in some countries For transplantation research
Chondrocytes	Krishnamurithy et al., 2011 (128), Diaz-Prado et al., 2010 (129), Jin et al., 2007 (130)	Research for chondrocyte transplantation in repair of joint cartilage
Fibroblasts	Mahmoudi-Rad et al., 2013 (131)	Research for the preparation of temporary skin substitutes
Epidermal keratinocytes	Huang et al., 2013 (132)	Research for the preparation of dermal scaffolds for skin structure reconstruction
Autologous melanocytes	Redondo et al., 2011 (133)	Growth of melanocytes on denuded AM for vitiligo treatment
Urothelial cells	Jerman et al., 2014 (64), Sharifiaghdas et al., 2007 (64,134)	Research for the preparation of the urothelium for transplantations <i>in vivo</i>
Human alogenous primary fibroblasts and keratocytes	Wilshaw et al., 2008 (135)	Research for the preparation of a construct for the treatment of diabetic leg ulcers, corneal defects and burns
Mesenchymal corneal stem cells, explant cultivation technique	Lužnik et al., 2016 (87)	As a research model and a potential therapeutic product
Mesenchymal stem cells obtained from adipose tissue (hADM-SC)	Gholipoumalekabadi et al., 2016 (136)	Research: preparation of hADM-SC to promote tissue regeneration and treat skin damage
Mesenchymal stem cells obtained from bone marrow	Chehelcheraghi et al., 2016 (137), Tan et al., 2011 (138)	Research: AM scaffold for mesenchymal stem cell differentiation
Oral mucosa epithelium	Dobrowolski et al., 2015 (139), Amemiya et al., 2015 (140)	Reconstruction of the oral mucosa surface and the ocular surface
Lacrimal gland acinar cells	Tiwari et al., 2012 (141), Schrader et al., 2007 (142)	As a research model and a potential therapeutic product
Cell differentiation from AM and Wharton's jelly	Sanluis Verdes et al., 2017 (143)	Research: AM as a scaffold for cells that differentiate into cells resembling nerve cells
Bevacizumab medicine	Mayer et al., 2013 (144)	As a scaffold for medicinal treatment of corneal ulcers

3 Preparation of AM for scaffold use

Due to the possibility of bacterial infection with vaginal microbiota, AM is always harvested during an elective caesarean section (50-52). The donor (women giving birth) must be informed

about the intended AM use for research or clinical purposes and must give her consent for AM to be harvested.

The optimal AM storage method shall meet the following conditions: a) it allows AM to maintain the properties relevant for its use as a scaffold; b) it preserves functionality and sterility of AM;




Figure 2: Examples of different AM scaffolds. Different cell types can be grown on A) AM epithelium (intact AM) B) basal lamina of AM (denuded AM) or C) AM stroma.

c) it is simple to use (53). The legislation requires that prior to its use for clinical purposes AM is tested for any potential infection with various viruses or bacteria. Since in some cases AM should be quarantined for another 6 months, fresh AM is rarely used (54). The most common AM storage methods are: a) storage of fresh AM at $-80\text{ }^{\circ}\text{C}$ (in a phosphate buffer solution - DMSO (dimethyl sulfoxide) or a Modified Eagle Medium (MEM) – glycerol solution) or b) freeze drying (13,54). Other methods like air drying, treatment of AM with glutaraldehyde and polytetrafluoroethylene or lyophilisation are less frequently used (2,13,50).

Various studies have shown that different AM processing, storing and sterilization methods can affect AM properties, whereas Adds et al. could not detect any differences in the clinical effective-

ness of AM when used either fresh or frozen (stored in 50 % glycerol for half a year at $-80\text{ }^{\circ}\text{C}$) (51). AM freezing in 50 % glycerol does not allow survival of AM cells but preserves its basic morphology. One of the bigger obstacles in using AM as a scaffold for the cultivation of different cells is in the lack of studies that would determine the optimum AM storage method. Different studies demonstrated the influence of AM processing and storage methods on the AM properties that were relevant for cell culturing, such as AM mechanical properties, the ability of cell adhesion and proliferation to the AM, reduced content or release of growth factors, and altered properties of the basal lamina. Nevertheless different processing and storage methods (freezing in glycerol, Hank's balanced salt solution, lyophilisation) were suitable for cell growth (53,60-62).

If AM is used as a scaffold, it can be used with (intact AM) or without AEC (denuded AM) (3,28,63). AEC can be removed in one of several ways: a) by treatment with EDTA or with dispase; b) with thermolysin (3,28,64); or c) by treatment with SDS detergent (sodium dodecyl sulphate) (3).

AM for scaffold use can also be modified using other methods: TG-2 transglutaminase increases the mechanical strength of the AM and its resistance to proteolytic / collagenase degradation, but does not affect the adhesion, growth, proliferation and differentiation of cells (65). The mechanical strength of AM and thereby its suitability for use in reconstructive urology can be increased with polymeric nanofibres made by electrostatic spinning process (66). AM modified with carbodiimide or a combination of carbodiimide and L-lysine was shown to be a very suitable scaffold for the cultivation of limbal stem cells (67,68).

4 AM as a source of stem cells

AM hosts two cell populations that are believed to have stem-cell properties, i.e. AEC and AMSC. The advantage of stem cells from adult tissues and stem cells from AM is that they - unlike embryonic stem cells - do not form teratomas (69-71).

AEC and AMSC are capable of differentiation to cells of all three embryonic germ layers in *in vitro* conditions (72,73). AEC express CD105/CD90, CD44/CD90 in CD271/CD44, SSEA3 and SSEA4, STRO1, TRA1-60, TRA1-81, OCT4, SOX2 and Nanog markers (69,74). AMSC express typical mesenchymal markers (CD73, CD90, CD105) as well as pluripotency markers, such as e.g. OCT4, SOX2, Rex1, Nanog.

Owing to their anti-inflammatory activity (inhibition of the activated T lymphocyte proliferation and inflammatory cytokines Th1 secretion, regulatory T-cells induction, etc.) (20,75), ability to promote epithelization (by AEC's excretion of bFGF, HGF, EGF, KGF factors) (26,76) and their anti-angiogenic activity (by AEC's and AMSC's excretion of endostatin, thrombospondin-1 and the tissue inhibitors of metalloproteinases-1 and -2) (26,77,78), AM cells are suitable for therapeutic purposes. In recent years, several studies have been performed on various animal models to study the effect of AM cells in Parkinson's and Alzheimer's disease, multiple sclerosis, spinal cord injuries, cerebral and cardiac arrest, pulmonary disease, hepatic fibrosis, muscular dystrophy, diabetes, and bone and cartilage injuries. Furthermore, clinical studies are being conducted to investigate the use of AM cells for the treatment of burns, Crohn's disease, diabetic foot, haematopoietic diseases, metabolic disorders, diabetes and

rheumatoid arthritis (79). Further clinical studies will have to comprehensively evaluate the effect of AM-derived stem cells on the course of disease and treatment in humans.

5 AM as a scaffold for cultivating corneal (limbal) epithelial stem cells

Corneal stem cells enable renewal of corneal epithelium. They are thought to reside in the basal layer of the limbal epithelium and are therefore also called limbal epithelial stem cells (LESC). When these LESCs become damaged (dysfunctional) or deficient, the corneal epithelium loses its regenerative ability and is gradually replaced by conjunctival epithelium. Limbal epithelial stem cell deficiency leads to recurrent or persistent epithelial defects, corneal neovascularisation, chronic ocular surface inflammation, and scarring that, in turn, lead to painful loss of vision (Figure 3A). The etiology of limbal epithelial stem cell deficiency is most commonly acquired (chemical or thermal injuries, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, prolonged soft contact lens wear), and rarely congenital, like in aniridia (80).

Limbal stem cell deficiency (LSCD) can either be partial or total and may affect one (uni-) or both eyes (bilateral). Treatment of LSCD is complex and often lifelong (81). Total LSCD requires transplantation of healthy LESCs (82,83), which can be of autologous or allogeneic origin (from a cadaver or a living-related donor). Currently, there are two major surgical approaches used for LESCs transplantation: 1) the conventional surgical procedure, where healthy donor limbal tissue is transplanted directly, or 2) the indirect cultivated limbal epithelial

transplantation (CLET), where from a small (1–2 mm²) limbal biopsy corneal epithelium containing LSCs is cultured *ex vivo* before transplantation (84). Both techniques have their advantages and disadvantages. Since 1997, when Pellegrini et al. (84) described the first successful application of CLET, several protocols for limbal epithelium cultivation have been developed worldwide.

Clinically, two main culture protocols proved to be most useful: 1) the suspension method – where suspended LSCs are co-cultured with a mouse fibroblast feeder layer (fibroblasts isolated from embryonic mice – 3T3 J2), and 2) the explant method – where a small limbal tissue biopsy is directly cultured on a human AM. As the basal lamina of AM is similar to the basal lamina of corneal and conjunctival epithelium, it is particularly suitable as a biological scaffold for *ex vivo* LSC culture (23). The micro-environment in which the cells are cultured is extremely important. In 2000, Koizumi was the first one to use AM as a biological scaffold for LSC cultivation (23). For cultivation, intact thawed (with preserved amniotic epithelium) (2,85) or denuded AM (23,86) can be used. AM with the epithelial side up is fastened into the plastic rings (Figure 3B). Limbal biopsy (in the explant method) is then placed on the top of the fastened AM (86). Under standard *ex vivo* conditions, cultured limbal epithelial cells proliferate and overgrow the AM scaffold in 2–3 weeks (85–87).

Although different protocols for *ex vivo* LSC cultivation are used worldwide, long-term success of CLET has been reported to exceed 75 % with approximately 3 % rate of immune rejections in case of allogeneic CLET (89).

Different centres worldwide favour the use of denuded or intact AM (85,86,90). Koizumi et al. compared the use of de-

nuded and intact AM for LESC cultivation (90). With intact AM usage, the phenotype of the growing epithelium was more similar to the limbal epithelium (presumably containing more stem cells), while the epithelium grown on denuded AM was more similar to a mature corneal epithelium (2,90). The stromal side of AM could also be used for limbal epithelium cultivation, as it contains particularly high concentrations of nerve growth factor (NGF), which plays an essential role in epithelium development and survival of stem cells (85). Solomon et al. have reported that the stromal side of AM in the cultivated limbal epithelium inhibits lipopolysaccharide-induced increased expression of IL-1 α and β (29).

Since 2000, AM has been successfully used in clinical practice in Slovenia (91): to promote healing of corneal ulcers, for management of corneal perforations, for eye surface reconstruction surgeries, and for acute treatment of thermal and chemical injuries (25). At the Eye Hospital, University Medical Centre, Ljubljana, after having obtained the consent of the Medical Ethics Commission of the University Medical Centre Ljubljana, we started with the explant technique of cadaveric limbal tissue cultivation on AM for research purposes. The first results of *ex vivo* limbal tissue cultivation on AM (explant technique) are comparable with the results of previously published studies. In addition, we were among the first to demonstrate the presence of cells that were positive for mesenchymal stem cell markers (CD73/CD90/CD105+ in CD45-) (87).

In order to transplant an adequate number of cultured LSCs into the diseased patient's eye, *ex vivo* identification of LSCs prior to surgery is very important for quality assessment of the cultured limbal/corneal epithelium (84). The stem cell potential can be determined




Figure 3: A) Conjunctivitis and corneal scarring (arrow) due to the lack or damage of limbal epithelial stem cells (LESC) (Photo: Petra Schollmayer). B) Human AM, mounted on the scaffold and prepared for LESC cultivation (Photo: Zala Lužnik).

with functional tests that identify live LESC in culture, and are still the gold standard for determining the number of stem cells in culture (92). In recent years, several putative LESC molecular markers have been identified. Although to date no specific LESC marker has yet been identified, based on the expression profile of several positive and negative differentiation markers, we can indirectly identify stem cells *in situ* (93).

Using immunohistochemical methods we could observe cultured epithelial growth on both sides of AM. The epithelium was stratified, non-keratinising, and the cells in the basal epithelial layer expressed the transcriptional factor p63, which is one of the leading putative LESC markers. Individual cells were positive for Ki67, a proliferation marker, which indicates the proliferation potential of cultured limbal epithelium. Limbal epithelial growth on the epithelial side of AM has already been well described in literature, however, there are still contradictory opinions in regard to the ability of the limbal epithelium to grow on the stromal side of AM. Zakaria et al. reported that they did not observe limbal epithelial growth on the stromal

side of AM, but they used a different culture medium than our group (86).

The content of limbal mesenchymal stromal stem cell (MSC) in limbal cultures, grown on AM, has not yet been reported in the literature. Our experiments confirm that AM enables more selective growth of epithelial cells, as the proportion of cells positive for mesenchymal stem cell markers (CD73/CD90/CD105+ and CD45-) was statistically significantly lower compared to control cultures. Szabo et al. reported 22 % of cells in limbal cultures to be positive for CD184 and only 0.6 % positive for CD117 (94), both representing putative surface markers for LESC. In our study, we identified 2–7 % of cells that expressed CD184 and CD117. Clinical studies revealed that a favourable clinical outcome of CLET was achieved if the content of LESC in the transplanted epithelium was at least 3 % (92). Based on our current experimental results, this threshold can be reached with the limbal explant technique. With an interdisciplinary approach we would like to introduce this new treatment method for managing severe total limbal stem cell deficiency with cultivated LESC transplantation to Slovenia in the near future.

6 AM as a scaffold for urothelial cells

The urinary bladder wall consists of four layers: the urothelium, submucosa, muscular layer and the adventitia (95). The urothelium is composed of three to seven layers of cells, divided according to their position into superficial, intermediate, and basal cells. The superficial urothelial (umbrella) cells are highly specialised and achieve a high level of differentiation, which significantly contributes to the maintenance of the blood-urine barrier (95-97). The basal lamina separates the urothelium from the underlying submucosa, which consists of the lamina propria and connective tissue (98,99).

Various pathological conditions, such as congenital anomalies, trauma, inflammations or malignancies, require reconstruction of the urinary bladder (100,101). In 2013, there were 344 new cases of bladder cancer detected in Slovenia. Non-invasive cancer of the urinary bladder (non-invasive papillary urothelial carcinoma) is treated by transurethral resection (partial or complete removal of the tumour through the urethra), whereas invasive bladder cancer or large, recurrent, non-invasive tumours or tumours that are unresponsive to the treatment require cystectomy (removal of a part of the urinary bladder or of the whole organ) (102). In order to prolong the survival of patients with bladder cancer, new therapies are being developed. One of these is a tissue-engineering approach. In 2006, Atala et al. (98) described the preparation of a bladder construct that was used for a urinary bladder reconstruction in seven patients with myelomeningocele. First, the patients underwent bladder biopsies; urothelial and muscle cells were cultured *in vitro* and then seeded on a collagen

scaffold or a scaffold composed of collagen and poly glycolic acid (PGA). After 7 weeks of culturing, the constructs were wrapped in the omentum and implanted in the patients. The patients were then followed up for 22–61 weeks after surgery. The constructs of autologous cells seeded on the collagen/PGA scaffolds, which were wrapped in the omentum prior to implantation, proved to be suitable for use in patients requiring cystoplasty (98). However, when considering *in vivo* transplantation, it is important that tissue-engineered urothelium already forms a functional phenotype to provide immediate protection of the underlying stroma. To our knowledge, the AM is currently the only scaffold which enables the *in vitro* development of tissue-engineered urothelium with molecular and ultrastructural properties comparable to that of native urothelium (64).

Various biological materials have been used for urinary bladder reconstruction, albeit with a limited success. In 2014, Jerman and coworkers from the Institute of Cell Biology at the Faculty of Medicine, University of Ljubljana used AM as a scaffold for the growth of normal urothelial cells (64). Normal porcine urothelial (NPU) cells were seeded on a) AM epithelium (eAM), b) AM basal lamina, i.e. denuded AM (dAM), or c) connective tissue (stroma) of AM (sAM). The proliferation and differentiation of NPU cells were followed for 3 weeks. By using electron microscopy, histochemical and immunofluorescence techniques, we provided evidence that all three AM scaffolds enable the development of the urothelium. The fastest growth and the highest differentiation of NPU cells were demonstrated on the sAM scaffold, which enables the development of tissue-engineered urothelium with molecular and ultrastructural properties comparable to that of the native urothelium with fun-




Figure 4: A) Wound healing phases. (B) During treatment, different cell types are present in the wound (summarized from Rožman et al., 2011) (104).

ctional blood-urine barrier. Superficial urothelial cells expressed uroplakins, which organized into urothelial plaques, and were well connected with tight junctions. On the sAM scaffold, NPU cells formed a new basal lamina composed of type IV collagen. It is believed that the paracrine role of AM as well as the topography and composition of the extracellular matrix of AM are important for the formation of such urothelium (64).

Notably, the highly differentiated urothelia on the sAM scaffolds provide important experimental models for drug delivery studies and developing tissue engineering strategies considering that subtle differences are identified before translation to the clinical settings.

7 Amniotic and amnio-chorionic membranes for the treatment of chronic wounds

Wound healing is a complex process consisting of inflammatory, proliferative and remodelling phase (Figure 4A) (104). The process involves a synchronised function of several cell types. The most dynamic wound healing processes occurs in the first days after injury, when immune cells and platelets migrate to the site of injury, triggering coagulation and inflammation. Immediately after the formation of the wound, the platelet count at the site of the injury increases while the number of neutrophils rises within 24 hours after the injury. In the following days, the number of macrophages, fibro-

blasts and lymphocytes increases as well (Figure 4B (104)). If the inflammatory process is not completed within a week, the wound is regarded as chronic. The chronic wound fails to heal even after two months (105). Despite extensive research, molecular mechanisms that contribute to the onset of chronic wounds have still not been fully explained (106). The wound healing process in embryo differs greatly from the wound healing in an adult: inflammation after an injury to embryo is lesser, resulting in a smaller scar and better tissue healing.

To support the wound healing process, AM or amnio-chorionic membrane (ACM) is used. ACM is thicker, stronger, and contains higher amounts of growth factors, which is of particular importance for the topical use.

AM or ACM for therapeutic purposes is used as fresh or frozen. Fresh AM is used mainly in underdeveloped countries, where the procurement and use of expensive and huge freezers for tissue storage at -80°C represents a major obstacle (107,108). In the treatment of chronic wounds, the use of commercially available dehydrated AM (Purion[®], MiMedx, USA) or ACM (Epifix[®], MiMedx, USA) produces an effect comparable to that achieved by the use of fresh or frozen AM or ACM.

AM and ACM are used mainly for the treatment of diabetic foot, venous or arterial ulcers and other chronic wounds (109,110). In randomised controlled clinical trial on diabetic foot healing, the use of AM and ACM improved the process of wound healing: in most cases the process was successfully completed (92 % in 6 weeks) (106). A high rate of success was also shown by some other studies (111-113).

At the Clinical Department of Surgical Infections of the Ljubljana University Medical Centre, four patients with chro-

nic wounds were treated with ACM. Two of the patients had diabetes and chronic wounds on the ankle and the foot, respectively. The third patient had a chronic wound of unknown aetiology above the sternum, and the fourth patient was a child with chronic burn wound on the front side of his chest. The surgical treatment and the treatment according to the latest guidelines for wound care was unsuccessful, therefore all four patients received dehydrated ACM (Epifix[®]) once a week for three consecutive weeks. A great improvement was observed after 14 days, i.e. after the second cycle of ACM, when the wound surface decreased for more than 30 %. After three applications of ACM the wounds healed completely, and there were no recurrences (114,115).

8 Conclusion

With the development of regenerative medicine mechanical properties of AM (stability, elasticity and plasticity) came to the fore. These properties are attributable mainly to the molecules of the extracellular matrix that forms the basal lamina and extracellular matrix of the stroma and make AM a good scaffold for use in tissue engineering and regenerative medicine. In orthopaedics, micronized dehydrated human AM is used to reduce or prevent soft tissue inflammation (e.g. fasciitis) or osteoarthroses (116). In Slovenia, AM is used in ophthalmology since 2009 either as a graft, patch or a filler for the treatment of various eye injuries. Since glycerol-frozen AM can be successfully used as a scaffold for LEMC cultivation, the Department of Ophthalmology, in the cooperation with the Centre for Blood Transfusion Medicine of the Republic of Slovenia, has started to develop a procedure that will allow for the preparation of clinically appropriate, on AM cultiva-

ted LEMC for the treatment of a range of LEMC-deficiency associated disorders at different stages of progression (118). Since AM scaffolds enables the development of highly differentiated urothelia, the Institute of Cell Biology at Faculty of Medicine continues with development of tissue engineered constructs of AM and urothelium for drug delivery studies and for developing new tissue engineering strategies considering that subtle differences are identified before translation to the clinical settings.

9 Acknowledgement

The authors sincerely thank the Department of Gynaecology of the University Medical Centre in Ljubljana, and all the women who donated their amniotic membrane for research or clinical use. Sincere thanks also to Ms. Cvetana Tavzes for proofreading. The work was supported by the Slovenian Research Agency (Grant No. P3-0108, P3-0371, J3-7494 and the Young Researcher Program).

Literatura

- Méhats C, Schmitz T, Marcellin L, Breuiller-Fouché M. [Biochemistry of fetal membranes rupture]. *Gynécologie Obstétrique Fertilité*. 2011 Jun;39(6):365–9.
- Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. *Surv Ophthalmol*. 2004 Jan-Feb;49(1):51–77.
- Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater*. 2008 Apr;15:88–99.
- Ockleford C, Malak T, Hubbard A, Bracken K, Burton SA, Bright N, et al. Confocal and conventional immunofluorescence and ultrastructural localisation of intracellular strength-giving components of human amniochorion. *J Anat*. 1993 Dec;183(Pt 3):483–505.
- Kobayashi K, Miwa H, Yasui M. Inflammatory mediators weaken the amniotic membrane barrier through disruption of tight junctions. *J Physiol*. 2010 Dec;588(Pt 24):4859–69.
- Fukuda K, Chikama T, Nakamura M, Nishida T. Differential distribution of subchains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea, and conjunctiva. *Cornea*. 1999 Jan;18(1):73–9.
- Meinert M, Eriksen GV, Petersen AC, Helmig RB, Laurent C, Ulbjerg N, et al. Proteoglycans and hyaluronan in human fetal membranes. *Am J Obstet Gynecol*. 2001 Mar;184(4):679–85.
- Wolf HJ, Schmidt W, Drenckhahn D. Immunocytochemical analysis of the cytoskeleton of the human amniotic epithelium. *Cell Tissue Res*. 1991 Nov;266(2):385–9.
- Malak TM, Ockleford CD, Bell SC, Dalgleish R, Bright N, Macvicar J. Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes. *Placenta*. 1993 Jul-Aug;14(4):385–406.
- Kolega J, Manabe M, Sun TT. Basement membrane heterogeneity and variation in corneal epithelial differentiation. *Differentiation*. 1989 Oct;42(1):54–63.
- Gipson IK, Spurr-Michaud SJ, Tisdale AS. Anchoring fibrils form a complex network in human and rabbit cornea. *Invest Ophthalmol Vis Sci*. 1987 Feb;28(2):212–20.
- Endo K, Nakamura T, Kawasaki S, Kinoshita S. Human amniotic membrane, like corneal epithelial basement membrane, manifests the alpha5 chain of type IV collagen. *Invest Ophthalmol Vis Sci*. 2004 Jun;45(6):1771–4.
- Riau AK, Beuerman RW, Lim LS, Mehta JS. Preservation, sterilization and de-epithelialization of human amniotic membrane for use in ocular surface reconstruction. *Biomaterials*. 2010 Jan;31(2):216–25.
- Meller D, Tseng SC. Conjunctival epithelial cell differentiation on amniotic membrane. *Invest Ophthalmol Vis Sci*. 1999 Apr;40(5):878–86.
- Velez I, Parker WB, Siegel MA, Hernandez M. Cryopreserved amniotic membrane for modulation of periodontal soft tissue healing: a pilot study. *J Periodontol*. 2010 Dec;81(12):1797–804.
- Choi JA, Jin HJ, Jung S, Yang E, Choi JS, Chung SH, et al. Effects of amniotic membrane suspension in human corneal wound healing in vitro. *Mol Vis*. 2009 Nov;15:2230–8.
- Dua HS, Azuara-Blanco A. Amniotic membrane transplantation. *Br J Ophthalmol*. 1999 Jun;83(6):748–52.
- Ohshima M, Tokunaga K, Sato S, Maeno M, Otsuka K. Laminin- and fibronectin-like molecules produced by periodontal ligament fibroblasts under serum-free culture are potent chemoattractants for gingival epithelial cells. *J Periodontol Res*. 2003 Apr;38(2):175–81.
- Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res*. 2000 Mar;20(3):173–7.

20. Li J, Koike-Soko C, Sugimoto J, Yoshida T, Okabe M, Nikaido T. Human Amnion-Derived Stem Cells Have Immunosuppressive Properties on NK Cells and Monocytes. *Cell Transplant*. 2015;24(10):2065–76.
21. Li H, Niederhorn JY, Neelam S, Mayhew E, Word RA, McCulley JP, et al. Immunosuppressive factors secreted by human amniotic epithelial cells. *Invest Ophthalmol Vis Sci*. 2005 Mar;46(3):900–7.
22. Gicquel JJ, Dua HS, Brodie A, Mohammed I, Suleman H, Lazutina E, et al. Epidermal growth factor variations in amniotic membrane used for ex vivo tissue constructs. *Tissue Eng Part A*. 2009 Aug;15(8):1919–27.
23. Koizumi N, Fullwood NJ, Bairaktaris G, Inatomi T, Kinoshita S, Quantock AJ. Cultivation of corneal epithelial cells on intact and denuded human amniotic membrane. *Invest Ophthalmol Vis Sci*. 2000 Aug;41(9):2506–13.
24. Russo A, Bonci P, Bonci P. The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane. *Cell Tissue Bank*. 2012 Jun;13(2):353–61.
25. Cirman T, Beltram M, Schollmayer P, Rožman P, Kreft ME. Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia. *Cell Tissue Bank*. 2014 Jun;15(2):177–92.
26. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. *Cornea*. 2000 May;19(3):348–52.
27. Fidel PL Jr, Romero R, Ramirez M, Cutright J, Edwin SS, LaMarche S, et al. Interleukin-1 receptor antagonist (IL-1ra) production by human amnion, chorion, and decidua. *Am J Reprod Immunol*. 1994 Aug;32(1):1–7.
28. Dragin U, Kreft ME. Amniotic membrane in tissue engineering and regenerative medicine. *Zdravn vestn*. 2010;79(10):8707–715.
29. Solomon A, Rosenblatt M, Monroy D, Ji Z, Pflugfelder SC, Tseng SC. Suppression of interleukin 1 α and interleukin 1 β in human limbal epithelial cells cultured on the amniotic membrane stromal matrix. *Br J Ophthalmol*. 2001 Apr;85(4):444–9.
30. Heiligenhaus A, Bauer D, Meller D, Steuhl KP, Tseng SC. Improvement of HSV-1 necrotizing keratitis with amniotic membrane transplantation. *Invest Ophthalmol Vis Sci*. 2001 Aug;42(9):1969–74.
31. Sippel KC, Ma JJ, Foster CS. Amniotic membrane surgery. *Curr Opin Ophthalmol*. 2001 Aug;12(4):269–81.
32. He H, Li W, Chen SY, Zhang S, Chen YT, Hayashida Y, et al. Suppression of activation and induction of apoptosis in RAW264.7 cells by amniotic membrane extract. *Invest Ophthalmol Vis Sci*. 2008;49(10):4468–75.
33. Kim HS, Cho JH, Park HW, Yoon H, Kim MS, Kim SC. Endotoxin-neutralizing antimicrobial proteins of the human placenta. *J Immunol*. 2002;168(5):2356–64.
34. Buhimschi IA, Jabr M, Buhimschi CS, Petkova AP, Weiner CP, Saed GM. The novel antimicrobial peptide beta3-defensin is produced by the amnion: a possible role of the fetal membranes in innate immunity of the amniotic cavity. *Am J Obstet Gynecol*. 2004 Nov;191(5):1678–87.
35. King AE, Paltoo A, Kelly RW, Sallenave JM, Bocking AD, Challis JR. Expression of natural antimicrobials by human placenta and fetal membranes. *Placenta*. 2007 Feb-Mar;28(2-3):161–9.
36. Ni J, Abrahamson M, Zhang M, Fernandez MA, Grubb A, Su J, et al. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. *J Biol Chem*. 1997 Apr;272(16):10853–8.
37. Akle CA, Adinolfi M, Welsh KI, Leibowitz S, McColl I. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. *Lancet*. 1981 Nov;2(8254):1003–5.
38. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. *Invest Ophthalmol Vis Sci*. 2001 Jun;42(7):1539–46.
39. Hammer A, Hutter H, Blaschitz A, Mahnert W, Hartmann M, Uchanska-Ziegler B, et al. Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. *Am J Reprod Immunol*. 1997 Feb;37(2):161–71.
40. Langer R, Vacanti J. Advances in tissue engineering. *J Pediatr Surg*. 2016 Jan;51(1):8–12.
41. Mungadi IA. Bioengineering tissue for organ repair, regeneration, and renewal. *J Surg Tech Case Rep*. 2012 Jul;4(2):77–8.
42. Nakanishi Y, Chen G, Komuro H, Ushida T, Kaneko S, Tateishi T, et al. Tissue-engineered urinary bladder wall using PLGA mesh-collagen hybrid scaffolds: a comparison study of collagen sponge and gel as a scaffold. *J Pediatr Surg*. 2003 Dec;38(12):1781–4.
43. Heidary Rouchi A, Mahdavi-Mazdeh M. Regenerative Medicine in Organ and Tissue Transplantation: Shortly and Practically Achievable? *Int J Organ Transplant Med*. 2015;6(3):93–8.
44. Mano JF, Silva GA, Azevedo HS, Malafaya PB, Sousa RA, Silva SS, et al. Natural origin biodegradable systems in tissue engineering and regenerative medicine: present status and some moving trends. *J R Soc Interface*. 2007 Dec;4(17):999–1030.
45. O'Brien FJ. Biomaterials and scaffolds for tissue engineering. *Mater Today*. 2011;14(3):88–95.
46. Vunjak-Novakovic G. The fundamentals of tissue engineering: scaffolds and bioreactors. *Novartis Found Symp*. 2003;249:34–46; discussion-51, 170–4, 239–41. <https://doi.org/10.1002/0470867973.ch4>.
47. Hsiao YC, Lee HW, Chen YT, Young TH, Yang TL. The impact of compositional topography of amniotic membrane scaffold on tissue morphogenesis of salivary gland. *Biomaterials*. 2011 Jul;32(19):4424–32.
48. Feng Y, Borrelli M, Reichl S, Schrader S, Geerling G. Review of alternative carrier materials for ocular surface reconstruction. *Curr Eye Res*. 2014 Jun;39(6):541–52.
49. Ramuta TZ, Kreft ME. Human Amniotic Membrane and Amniotic Membrane-Derived Cells: How Far Are We from Their Use in Regenerative and Reconstructive Urology? *Cell Transplant*. 2018 Jan;27(1):77–92.
50. Madhavan HN, Priya K, Malathi J, Joseph PR. Preparation of amniotic membrane for ocular surface reconstruction. *Indian J Ophthalmol*. 2002 Sep;50(3):227–31.

51. Addis PJ, Hunt CJ, Dart JK. Amniotic membrane grafts, “fresh” or frozen? A clinical and *in vitro* comparison. *Br J Ophthalmol*. 2001 Aug;85(8):905–7.
52. Addis PJ, Hunt C, Hartley S. Bacterial contamination of amniotic membrane. *Br J Ophthalmol*. 2001 Feb;85(2):228–30.
53. Thomasen H, Pauklin M, Steuhl KP, Meller D. Comparison of cryopreserved and air-dried human amniotic membrane for ophthalmologic applications. *Graefes Arch Clin Exp Ophthalmol*. 2009 Dec;247(12):1691–700.
54. Rahman I, Said DG, Maharajan VS, Dua HS. Amniotic membrane in ophthalmology: indications and limitations. *Eye (Lond)*. 2009 Oct;23(10):1954–61.
55. von Versen-Höyneck F, Syring C, Bachmann S, Möller DE. The influence of different preservation and sterilisation steps on the histological properties of amnion allografts—light and scanning electron microscopic studies. *Cell Tissue Bank*. 2004;5(1):45–56.
56. Hennerbichler S, Reichl B, Pleiner D, Gabriel C, Eibl J, Redl H. The influence of various storage conditions on cell viability in amniotic membrane. *Cell Tissue Bank*. 2007;8(1):1–8.
57. Ricci E, Vanosi G, Lindenmair A, Hennerbichler S, Peterbauer-Scherb A, Wolbank S, et al. Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model. *Cell Tissue Bank*. 2013 Sep;14(3):475–88.
58. Kruse FE, Jousseaume AM, Rohrschneider K, You L, Sinn B, Baumann J, et al. Cryopreserved human amniotic membrane for ocular surface reconstruction. *Graefes Arch Clin Exp Ophthalmol*. 2000 Jan;238(1):68–75.
59. Wolbank S, Hildner F, Redl H, van Griensven M, Gabriel C, Hennerbichler S. Impact of human amniotic membrane preparation on release of angiogenic factors. *J Tissue Eng Regen Med*. 2009 Dec;3(8):651–4.
60. Shortt AJ, Secker GA, Lomas RJ, Wilshaw SP, Kearney JN, Tuft SJ, et al. The effect of amniotic membrane preparation method on its ability to serve as a substrate for the ex-vivo expansion of limbal epithelial cells. *Biomaterials*. 2009 Feb;30(6):1056–65.
61. Niknejad H, Deihim T, Solati-Hashjin M, Peirovi H. The effects of preservation procedures on amniotic membrane’s ability to serve as a substrate for cultivation of endothelial cells. *Cryobiology*. 2011 Dec;63(3):145–51.
62. Rodríguez-Ares MT, López-Valladares MJ, Touriño R, Vieites B, Gude F, Silva MT, et al. Effects of lyophilization on human amniotic membrane. *Acta Ophthalmol*. 2009 Jun;87(4):396–403.
63. Hopkinson A, Shanmuganathan VA, Gray T, Yeung AM, Lowe J, James DK, et al. Optimization of amniotic membrane (AM) denuding for tissue engineering. *Tissue Eng Part C Methods*. 2008 Dec;14(4):371–81.
64. Jerman UD, Veranič P, Kreft ME. Amniotic membrane scaffolds enable the development of tissue-engineered urothelium with molecular and ultrastructural properties comparable to that of native urothelium. *Tissue Eng Part C Methods*. 2014 Apr;20(4):317–27.
65. Chau DY, Brown SV, Mather ML, Hutter V, Tint NL, Dua HS, et al. Tissue transglutaminase (TG-2) modified amniotic membrane: a novel scaffold for biomedical applications. *Biomed Mater*. 2012 Aug;7(4):045011.
66. Adamowicz J, Pokrywczyńska M, Tworzydło J, Kowalczyk T, van Breda SV, Tyloch D, et al. New Amniotic Membrane Based Biocomposite for Future Application in Reconstructive Urology. *PLoS One*. 2016 Jan;11(1):e0146012.
67. Ma DH, Lai JY, Cheng HY, Tsai CC, Yeh LK. Carbodiimide cross-linked amniotic membranes for cultivation of limbal epithelial cells. *Biomaterials*. 2010 Sep;31(25):6647–58.
68. Lai JY, Wang PR, Luo LJ, Chen ST. Stabilization of collagen nanofibers with L-lysine improves the ability of carbodiimide cross-linked amniotic membranes to preserve limbal epithelial progenitor cells. *Int J Nanomedicine*. 2014 Nov;9:5117–30.
69. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. *Stem Cells*. 2005 Nov-Dec;23(10):1549–59.
70. Kang NH, Hwang KA, Kim SU, Kim YB, Hyun SH, Jeung EB, et al. Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells. *Cancer Gene Ther*. 2012 Aug;19(8):517–22.
71. Simerman AA, Perone MJ, Gimeno ML, Dumesic DA, Chazenbalk GD. A mystery unraveled: nontumorigenic pluripotent stem cells in human adult tissues. *Expert Opin Biol Ther*. 2014 Jul;14(7):917–29.
72. Parolini O, Soncini M, Evangelista M, Schmidt D. Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine? *Regen Med*. 2009 Mar;4(2):275–91.
73. Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring HJ, Evangelista M, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. *Stem Cells*. 2008 Feb;26(2):300–11.
74. Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. *Biol Reprod*. 2007 Sep;77(3):577–88.
75. Pianta S, Bonassi Signoroni P, Muradore I, Rodrigues MF, Rossi D, Silini A, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. *Stem Cell Rev*. 2015 Jun;11(3):394–407.
76. Silini AR, Cargnoni A, Magatti M, Pianta S, Parolini O. The Long Path of Human Placenta, and Its Derivatives, in Regenerative Medicine. *Front Bioeng Biotechnol*. 2015 Oct;3:162.
77. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. *Blood*. 2010 Jun;115(22):4605–13.
78. Niknejad H, Paeini-Vayghan G, Tehrani FA, Khayat-Khoei M, Peirovi H. Side dependent effects of the human amnion on angiogenesis. *Placenta*. 2013 Apr;34(4):340–5.

79. De D, Kmiecik G, Cargnoni A, Parolini O. Placenta-Derived Cells and Their Therapeutic Applications. V: Templeton NS, ur. Gene and Cell Therapy. Združene države Amerike: CRC Press; 2015. p. 773–94.
80. Puangsricharern V, Tseng SC. Cytologic evidence of corneal diseases with limbal stem cell deficiency. *Ophthalmology*. 1995 Oct;102(10):1476–85.
81. Bakhtiari P, Djalilian A. Update on limbal stem cell transplantation. *Middle East Afr J Ophthalmol*. 2010 Jan;17(1):9–14.
82. Meller D, Pires RT, Tseng SC. Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane cultures. *Br J Ophthalmol*. 2002 Apr;86(4):463–71.
83. Li W, Hayashida Y, He H, Kuo CL, Tseng SC. The fate of limbal epithelial progenitor cells during explant culture on intact amniotic membrane. *Invest Ophthalmol Vis Sci*. 2007 Feb;48(2):605–13.
84. Pellegrini G, Traverso CE, Franzini AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. *Lancet*. 1997 Apr;349(9057):990–3.
85. Grueterich M, Tseng SC. Human limbal progenitor cells expanded on intact amniotic membrane ex vivo. *Arch Ophthalmol*. 2002 Jun;120(6):783–90.
86. Zakaria N, Koppen C, Van Tendeloo V, Berneman Z, Hopkinson A, Tassignon MJ. Standardized limbal epithelial stem cell graft generation and transplantation. *Tissue Eng Part C Methods*. 2010 Oct;16(5):921–7.
87. Lužnik Z, Hawlina M, Maličev E, Bertolin M, Kopitar AN, Ihan A, et al. Effect of Cryopreserved Amniotic Membrane Orientation on the Expression of Limbal Mesenchymal and Epithelial Stem Cell Markers in Prolonged Limbal Explant Cultures. *PLoS One*. 2016 Oct;11(10):e0164408.
88. Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 years of cultured limbal epithelial cell therapy: a review of the outcomes. *J Cell Biochem*. 2011 Apr;112(4):993–1002.
89. Ahmad S, Osei-Bempong C, Dana R, Jurkunas U. The culture and transplantation of human limbal stem cells. *J Cell Physiol*. 2010 Oct;225(1):15–9.
90. Koizumi N, Rigby H, Fullwood NJ, Kawasaki S, Tanioka H, Koizumi K, et al. Comparison of intact and denuded amniotic membrane as a substrate for cell-suspension culture of human limbal epithelial cells. *Graefes Arch Clin Exp Ophthalmol*. 2007 Jan;245(1):123–34.
91. Mikek K, Pfeifer V, Drnovšek-Olup B. Amniotic Membrane Transplantation in the Ocular Surgery. *Zdrav Vestn*. 2004;73:4.
92. Di Iorio E, Ferrari S, Fasolo A, Böhm E, Ponzin D, Barbaro V. Techniques for culture and assessment of limbal stem cell grafts. *Ocul Surf*. 2010 Jul;8(3):146–53.
93. Burman S, Sangwan V. Cultivated limbal stem cell transplantation for ocular surface reconstruction. *Clin Ophthalmol*. 2008 Sep;2(3):489–502.
94. Szabó DJ, Noer A, Nagymihály R, Josifovska N, Andjelic S, Veréb Z, et al. Long-Term Cultures of Human Cornea Limbal Explants Form 3D Structures Ex Vivo - Implications for Tissue Engineering and Clinical Applications. *PLoS One*. 2015 Nov;10(11):e0143053.
95. Birder L, Andersson KE. Urothelial signaling. *Physiol Rev*. 2013 Apr;93(2):653–80.
96. Acharya P, Beckel J, Ruiz WG, Wang E, Rojas R, Birder L, et al. Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epithelium. *Am J Physiol Renal Physiol*. 2004 Aug;287(2):F305–18.
97. Hicks RM. The mammalian urinary bladder: an accommodating organ. *Biol Rev Camb Philos Soc*. 1975 May;50(2):215–46.
98. Paner GP, Ro JY, Wojcik EM, Venkataraman G, Datta MW, Amin MB. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. *Am J Surg Pathol*. 2007 Sep;31(9):1420–9.
99. Romih R, Korošec P, de Mello W Jr, Jezernik K. Differentiation of epithelial cells in the urinary tract. *Cell Tissue Res*. 2005 May;320(2):259–68.
100. Mahfouz W, Elsalmy S, Corcos J, Fayed AS. Fundamentals of bladder tissue engineering. *Afr J Urol*. 2013;19(2):51–7.
101. El-Taji OM, Khattak AQ, Hussain SA. Bladder reconstruction: the past, present and future. *Oncol Lett*. 2015 Jul;10(1):3–10.
102. Onkološki inštitut Ljubljana. Rak sečnega mehurja, ledvičnega meha in sečevoda. Onkološki inštitut; 2016 [cited 2017 Dec 2]. Available from: https://www.onko-i.si/za_javnost_in_bolnike/vrste_raka/urogenitalni_raki/#c23082016
103. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. *Lancet*. 2006 Apr;367(9518):1241–6.
104. Rožman P, Semenič D, Smrke DM. The Role of Platelet Gel in Regenerative Medicine. V: Wislet-Gendebien S, ed. *Advances in Regenerative Medicine: InTech*. 2011. 105.
105. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. *Am J Surg*. 2004 May;187(5 5A):11S–6S.
106. Koob TJ, Rennert R, Zabek N, Masee M, Lim JJ, Temenoff JS, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. *Int Wound J*. 2013 Oct;10(5):493–500.
107. Uçakhan OO, Köklü G, Firat E. Nonpreserved human amniotic membrane transplantation in acute and chronic chemical eye injuries. *Cornea*. 2002 Mar;21(2):169–72.
108. Mejía LF, Acosta C, Santamaría JP. Use of nonpreserved human amniotic membrane for the reconstruction of the ocular surface. *Cornea*. 2000 May;19(3):288–91.

109. Forbes J, Fetterolf DE. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. *J Wound Care*. 2012 Jun;21(6):290–6.
110. Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. *Int Wound J*. 2014 Dec;11(6):711–7.
111. Zelen CM, Serena TE, Denozieri G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. *Int Wound J*. 2013 Oct;10(5):502–7.
112. Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. *J Wound Care*. 2013;22(7):347-8, 50–1.
113. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. *Int Wound J*. 2014 Apr;11(2):122–8.
114. Ciringier M, Frangež I, Smrke D. Najnovejša metoda zdravljenja ran z alograftom amnijske membrane. In: Smrke D, Nikolič J, ur. *Sodobni pristopi za učinkovito zdravljenje okuženih kirurških in kroničnih ran*; 2014 Apr 24-25; Portorož, Slovenija. Klinični oddelek za kirurške okužbe, Kirurška klinika, Univerzitetni klinični center; 2014. p. 48-51.
115. Frangež I, Smrke D. Amniotic membrane allograft, new technology in chronic wound treatment. *Wound management*. Sarajevo: Doktor Magazin; 2014. p. 23.
116. Willett NJ, Thote T, Lin AS, Moran S, Raji Y, Sridaran S, et al. Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development. *Arthritis Res Ther*. 2014 Feb;16(1):R47.
117. Patel VR, Samavedi S, Bates AS, Kumar A, Coelho R, Rocco B, et al. Dehydrated Human Amnion/Chorion Membrane Allograft Nerve Wrap Around the Prostatic Neurovascular Bundle Accelerates Early Return to Continence and Potency Following Robot-assisted Radical Prostatectomy: Propensity Score-matched Analysis. *Eur Urol*. 2015 Jun;67(6):977–80.
118. Lužnik Z. Vzgoja in opredelitev človeških limbalnih epitelijskih matičnih celic (PhD Thesis). Ljubljana: Z. Lužnik; 2017.
119. Grueterich M, Espana EM, Tseng SC. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. *Surv Ophthalmol*. 2003 Nov-Dec;48(6):631–46.
120. Shortt AJ, Secker GA, Notara MD, Limb GA, Khaw PT, Tuft SJ, et al. Transplantation of ex vivo cultured limbal epithelial stem cells: a review of techniques and clinical results. *Surv Ophthalmol*. 2007 Sep-Oct;52(5):483–502.
121. Tsai RJ, Li L, Chen J. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells(1). *Am J Ophthalmol*. 2000 Oct;130(4):543.
122. Sharma S, Tandon R, Mohanty S, Sharma N, M V, Sen S, et al. Culture of corneal limbal epithelial stem cells: experience from benchtop to bedside in a tertiary care hospital in India. *Cornea*. 2011 Nov;30(11):1223–32.
123. Mariappan I, Maddileti S, Savy S, Tiwari S, Gaddipati S, Fatima A, et al. *In vitro* culture and expansion of human limbal epithelial cells. *Nat Protoc*. 2010 Aug;5(8):1470–9.
124. Ang LP, Tanioka H, Kawasaki S, Ang LP, Yamasaki K, Do TP, et al. Cultivated human conjunctival epithelial transplantation for total limbal stem cell deficiency. *Invest Ophthalmol Vis Sci*. 2010 Feb;51(2):758–64.
125. Pathak M, Olstad OK, Drolsum L, Moe MC, Smorodinova N, Kalasova S, et al. The effect of culture medium and carrier on explant culture of human limbal epithelium: A comparison of ultrastructure, keratin profile and gene expression. *Exp Eye Res*. 2016 Dec;153:122–32.
126. Zakaria N, Possemiers T, Dhubghaill SN, Leysen I, Rozema J, Koppen C, et al. Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. *J Transl Med*. 2014 Mar;12(1):58.
127. Vazirani J, Basu S, Kenia H, Ali MH, Kacham S, Mariappan I, et al. Unilateral partial limbal stem cell deficiency: contralateral versus ipsilateral autologous cultivated limbal epithelial transplantation. *Am J Ophthalmol*. 2014;157(3):584-90.e1–2. <https://doi.org/10.1016/j.ajo.2013.11.011>.
128. Krishnamurthy G, Shilpa PN, Ahmad RE, Sulaiman S, Ng CL, Kamarul T. Human amniotic membrane as a chondrocyte carrier vehicle/substrate: *in vitro* study. *J Biomed Mater Res A*. 2011 Dec;99(3):500–6.
129. Díaz-Prado S, Rendal-Vázquez ME, Muiños-López E, Hermida-Gómez T, Rodríguez-Cabarcos M, Fuentes-Boquete I, et al. Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair. *Cell Tissue Bank*. 2010 May;11(2):183–95.
130. Jin CZ, Park SR, Choi BH, Lee KY, Kang CK, Min BH. Human amniotic membrane as a delivery matrix for articular cartilage repair. *Tissue Eng*. 2007 Apr;13(4):693–702.
131. Mahmoudi-Rad M, Abolhasani E, Moravvej H, Mahmoudi-Rad N, Mirdamadi Y. Acellular amniotic membrane: an appropriate scaffold for fibroblast proliferation. *Clin Exp Dermatol*. 2013 Aug;38(6):646–51.
132. Huang G, Ji S, Luo P, Liu H, Zhu S, Wang G, et al. Accelerated expansion of epidermal keratinocyte and improved dermal reconstruction achieved by engineered amniotic membrane. *Cell Transplant*. 2013;22(10):1831–44.
133. Redondo P, Giménez de Azcarate A, Marqués L, García-Guzman M, Andreu E, Prósper F. Amniotic membrane as a scaffold for melanocyte transplantation in patients with stable vitiligo. *Dermatol Res Pract*. 2011;2011:532139.

134. Sharifiaghdas F, Hamzehiesfahani N, Moghadasali R, Ghaemimanesh F, Baharvand H. Human amniotic membrane as a suitable matrix for growth of mouse urothelial cells in comparison with human peritoneal and omentum membranes. *Urol J*. 2007;4(2):71–8.
135. Wilshaw SP, Kearney J, Fisher J, Ingham E. Biocompatibility and potential of acellular human amniotic membrane to support the attachment and proliferation of allogeneic cells. *Tissue Eng Part A*. 2008 Apr;14(4):463–72.
136. Gholipourmalekabadi M, Sameni M, Radenkovic D, Mozafari M, Mossahebi-Mohammadi M, Seifalian A. Decellularized human amniotic membrane: how viable is it as a delivery system for human adipose tissue-derived stromal cells? *Cell Prolif*. 2016 Feb;49(1):115–21.
137. Chehelcheraghi F, Eimani H, Homayoonsadraie S, Torkaman G, Amini A, Alavi Majd H, et al. Effects of Acellular Amniotic Membrane Matrix and Bone Marrow-Derived Mesenchymal Stem Cells in Improving Random Skin Flap Survival in Rats. *Iran Red Crescent Med J*. 2016 Jun;18(6):e25588.
138. Tan SL, Sulaiman S, Pinguang-Murphy B, Selvaratnam L, Tai CC, Kamarul T. Human amnion as a novel cell delivery vehicle for chondrogenic mesenchymal stem cells. *Cell Tissue Bank*. 2011 Feb;12(1):59–70.
139. Dobrowolski D, Orzechowska-Wylegala B, Wowra B, Wroblewska-Czajka E, Grolik M, Szczubialka K, et al. Cultivated Oral Mucosa Epithelium in Ocular Surface Reconstruction in Aniridia Patients. *BioMed Res Int*. 2015;2015:281870.
140. Amemiya T, Nakamura T, Yamamoto T, Kinoshita S, Kanamura N. Autologous transplantation of oral mucosal epithelial cell sheets cultured on an amniotic membrane substrate for intraoral mucosal defects. *PLoS One*. 2015 Apr;10(4):e0125391.
141. Tiwari S, Ali MJ, Balla MM, Naik MN, Honavar SG, Reddy VA, et al. Establishing human lacrimal gland cultures with secretory function. *PLoS One*. 2012;7(1):e29458.
142. Schrader S, Wedel T, Kremling C, Laqua H, Geerling G. Amniotic membrane as a carrier for lacrimal gland acinar cells. *Graefes Arch Clin Exp Ophthalmol*. 2007 Nov;245(11):1699–704.
143. Sanluis-Verdes A, Sanluis-Verdes N, Manso-Revilla MJ, Castro-Castro AM, Pombo-Otero J, Fraga-Mariño M, et al. Tissue engineering for neurodegenerative diseases using human amniotic membrane and umbilical cord. *Cell Tissue Bank*. 2017 Mar;18(1):1–15.
144. Mayer WJ, Grüterich M, Kook D, Sigg W, Kernt M, Messmer EM, et al. Modification of amniotic membrane as a depot carrier for bevacizumab - an *in-vitro* model for a slow release mechanism. *Curr Eye Res*. 2013 Apr;38(4):445–50.